Skip to main content
Publish date:

Dynavax To Present At Upcoming Investment Conferences

EMERYVILLE, Calif., Sept.

EMERYVILLE, Calif., Sept. 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that it will participate in the following investor conferences.

2021 Cantor Virtual Global Healthcare ConferenceDynavax Presentation: Thursday, September 30, 2021, 12:00 p.m. E.T.

Guggenheim 2nd Annual Vaccine and Infectious Disease ConferenceFireside Chat: Tuesday, October 5, 2021, 12:00 p.m. E.T.

H.C. Wainwright 2nd Hepatitis B Virus (HBV) Virtual ConferenceFireside Chat: Wednesday, October 13, 2021, 12:00 p.m. E.T.

All the conferences are being held virtually. A live webcast of each of the presentations will be available and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at

About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as an advanced vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit and follow the company on LinkedIn.


Nicole Arndt narndt@dynavax.com510-665-7264

Derek Cole, PresidentInvestor Relations Advisory Solutions

View original content to download multimedia:

SOURCE Dynavax Technologies